Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
ConclusionsEquivalent efficacy and similar pharmacokinetics, safety, and immunogenicity support bioequivalence of CT-P16 and EU-bevacizumab in patients with nsNSCLC.Trial registration numberNCT03676192. (Source: BioDrugs)
Source: BioDrugs - September 28, 2022 Category: Drugs & Pharmacology Source Type: research

The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
ConclusionThis study found that the CAR T cell gene therapies ciltacabtagene autoleucel and idecabtagene vicleucel for rrMM represent a significant economic burden for healthcare payers in the USA. (Source: BioDrugs)
Source: BioDrugs - September 27, 2022 Category: Drugs & Pharmacology Source Type: research

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog ®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
ConclusionsMYL-1601D demonstrated similar immunogenicity, efficacy, and safety profiles to Ref-InsAsp-US in patients with T1D over 24 weeks.Clinical Trial Registration ClinicalTrials.gov:NCT03760068. (Source: BioDrugs)
Source: BioDrugs - September 17, 2022 Category: Drugs & Pharmacology Source Type: research

PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
AbstractIn the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to overcome the limitations of protein inhibitors and its capability to target undruggable proteins. The PROTAC molecule consists of three components, a ubiquitin E3 ligase ligand, a linker, and a target protein ligand. The application of this technology is rapidly gaining momentum, especially in cancer therapy. In this review, we first look at the history of degraders, followed by a section on the ubiquitin proteasome system (UPS) and E3 ligases used in PROTAC development. PROTACs are dependent on ...
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research

Teserpaturev/G47 Δ: First Approval
This article summarizes the milestones in the develo pment of teserpaturev/G47Δ leading to this first approval for the treatment of malignant glioma. (Source: BioDrugs)
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research

PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
AbstractIn the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to overcome the limitations of protein inhibitors and its capability to target undruggable proteins. The PROTAC molecule consists of three components, a ubiquitin E3 ligase ligand, a linker, and a target protein ligand. The application of this technology is rapidly gaining momentum, especially in cancer therapy. In this review, we first look at the history of degraders, followed by a section on the ubiquitin proteasome system (UPS) and E3 ligases used in PROTAC development. PROTACs are dependent on ...
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
AbstractSystemic amyloidoses are characterized by the unrelenting deposition of autologous proteins as highly ordered fibrils in target organs. The ensuing, potentially fatal organ dysfunction is the result of the combined damage caused by the proteotoxic effect of prefibrillar species and by the cytotoxicity and the structural alterations produced by the amyloid fibrils. Current therapy is focused on eliminating the amyloid protein, thus extinguishing the amyloid cascade at its origin. While this approach may end the cell damage caused by prefibrillar aggregates and prevent further amyloid accumulation, the noxious effect...
Source: BioDrugs - September 12, 2022 Category: Drugs & Pharmacology Source Type: research

Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment
AbstractAcute respiratory distress syndrome (ARDS) is a severe respiratory disease associated with high morbidity and mortality in the  clinic. In the face of limited treatment options for ARDS, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have recently shown promise. They regulate levels of growth factors, cytokines, and other internal therapeutic molecules. The possible therapeutic mechanisms of MSC-EVs i nclude anti-inflammatory, cell injury repair, alveolar fluid clearance, and microbe clearance. The potent therapeutic ability and biocompatibility of MSC-EVs have enabled them as an alternative ...
Source: BioDrugs - September 10, 2022 Category: Drugs & Pharmacology Source Type: research

Therapeutic siRNA: State-of-the-Art and Future Perspectives
This article reviews the knowledge on siRNA design and chemical modification, as well as issues related to siRNA delivery that may be addressed using different delivery systems. Details on the mode of action and clinical status of the various siRNA therapeutics are provided, before giving an outlook on issues regarding the future of siRNA drugs and on their potential as one emerging standard modality in pharmacotherapy. Notably, this may also cover otherwise un-druggable diseases, the definition of non-coding RNAs as targets, and novel concepts of personalized and combination treatment regimens. (Source: BioDrugs)
Source: BioDrugs - August 23, 2022 Category: Drugs & Pharmacology Source Type: research